CHICAGO–(Small business WIRE)–OMX Ventures, a new everyday living sciences undertaking funds firm focused on investing in providers that run at the intersection of biology, big facts, and engineering, declared that Jamie Kasuboski, Ph.D. has joined the OMX staff of financial investment gurus as Vice President. Dr. Kasuboski was previously a enterprise investor at RA Money. The business has also declared that Kevin Ness, Ph.D., serial life sciences equipment entrepreneur and important trader in OMX Ventures Fund I, has joined the firm’s roster of advisors.
“We are really happy to welcome Jamie and Kevin to the OMX Ventures staff to aid our ongoing investment decision and organization building functions,” mentioned Craig Asher, OMX Ventures Taking care of Director. “OMX Ventures Fund I, which lifted $150 million in fully commited cash, is focusing on investments in early-phase organizations focused on foundational investigate equipment and devices, therapeutic improvement platforms, and synthetic biology organizations. Jamie comes on board as a new expense workforce member to increase our abilities as we foresee boosting our next fund later this year. We also look forward to performing with Kevin all over again as an advisor to our business and benefiting from his comprehensive skills in the life sciences instruments area.”
“I have labored with the OMX team users in all of my previous firms, and I know to start with-hand the exceptional worth and perception they convey to a begin-up organization and its team. With OMX Ventures, I know they are constructing a extremely particular new venture fund, and I am enthusiastic to be element of this journey with them,” claimed Dr. Ness.
The OMX Ventures Fund I was enthusiastically oversubscribed by traders, and OMX Ventures has been actively investing in new businesses, closing 16 discounts thus far with businesses which include Matterworks (next technology metabolomics), Inscripta (artificial biology instruments), TARA Biosystems (cardiac-concentrated drug discovery), Mythic Therapeutics (antibody engineering company), Compass Pathways (novel drug therapies for despair), and extra.
“I am excited to be part of this elite team of effective buyers and become section of a group targeted on figuring out and supporting businesses on the chopping edge of a new organic revolution,” said Dr. Kasuboski. “OMX has designed a robust foundation of equally traders and portfolio providers, and I am searching ahead to assisting increase OMX’s capabilities as we go on to make investments in and produce new organizations.”
About Jamie Kasuboski
Jamie is Vice President at OMX Ventures. Jamie earlier focused on early-phase biotech investing and firm development when at RA Capital and served on the board of Enara bio, Avilar Therapeutics and Endor Therapeutics. Prior to becoming a member of RA, he was a Director at Boehringer Ingelheim Venture Fund and served as a Board Director of each Tilos Therapeutics (obtained by Merck & Co.) and Rewind Therapeutics. He holds a B.S. in Biology with a small in Chemistry from Hillsdale School and a Ph.D. in Molecular and Cellular Biology from the College of Notre Dame.
About Kevin Ness
Kevin Ness has built a highly prosperous profession of developing very best-in-class tools for biologists and prosperous commercial ventures that progress genome producing and reading, and the one-cell sciences. Not too long ago, he was Main Executive Officer of Inscripta, and beforehand a co-founder of equally 10X Genomics (solitary-molecule and single-mobile sequencing technologies NASDAQ: TXG) and QuantaLife (droplet digital PCR technological innovation acquired by BioRad).
About OMX Ventures (pronounced “omics”):
OMX Ventures is a U.S. undertaking funds financial investment business focused on investing in a new period of bioengineering and its software for improved tools, medications, foods, industrial products, and far more. We are centered at the intersection of biology, massive info, and engineering, with targeted curiosity in daily life sciences tools, devices, therapeutics, and artificial biology. The firm was started in 2020 by associates who have co-invested and built successful businesses collectively in these fields for approximately a decade.
OMX Ventures initially fund, OMX Ventures Fund I, has lifted more than $150 million in committed money, which will be invested in primarily Seed and Collection A investments.
Our method is to make investments early, planting the seeds for productive firm development to build conviction and ownership in the most promising leaders by means of subsequent financial commitment and to advise and manual portfolio firms throughout their company daily life cycle. For far more information, please check out our website at http://www.omx.vc. Abide by us on Twitter and LinkedIn.